Skip to main content
Signal8

Senseonics Holdings, Inc. (SENS)

Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.

Sector: Industrial Instruments For Measurement, Display, and Control

Industry: Medical - Devices

Senseonics Holdings, Inc. logo

Senseonics Holdings, Inc.

NASDAQ:SENSHealthcare
-0.40%$7.48
AH Close$7.67+2.54%vs close
Mkt Cap$395.5M
Float50.12M
O/S52.87M
Inst Own39.4%
SI9.7%
Dilution
Senseonics Holdings, Inc. logoNASDAQ:SENS$7.48-0.40%